Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A B ayesian meta‐analysis of survival data
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aim: To conduct a systematic review and meta‐analysis to determine the risk of cardiovascular events and all‐cause mortality associated with sulphonylureas ( SUs ) vs other glucose lowering drugs in patients with T2DM ( T2DM ). Materials and methods: A systematic review of Medline, Embase, Cochrane and clinicaltrials.gov was conducted for studies comparing SUs with placebo or other antihyperglycaemic drugs in patients with T2DM . A cloglog model was used in the Bayesian framework to obtain comparative hazard ratios ( HRs ) for the different interventions. For the analysis of observational data, conventional fixed‐effect pairwise meta‐analyses were used. Results: The systematic review identified 82 randomized controlled trials ( RCTs ) and 26 observational studies. Meta‐analyses of RCT data showed an increased risk of all‐cause mortality and cardiovascular‐related mortality for SUs compared with all other treatments combined ( HR 1.26, 95% confidence interval [ CI ] 1.10‐1.44 and HR 1.46, 95% CI 1.21‐1.77, respectively). The risk of myocardial infarction was significantly higher for SUs compared with dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors and sodium‐glucose co‐transporter‐2 inhibitors ( HR 2.54, 95% CI 1.14‐6.57 and HR 41.80, 95% CI 1.64‐360.4, respectively). The risk of stroke was significantly higher for SUs than for DPP ‐4 inhibitors, glucagon‐like peptide‐1 agonists, thiazolidinediones and insulin. Conclusions: The present meta‐analysis showed an association between SU therapy and a higher risk of major cardiovascular disease‐related events compared with other glucose lowering drugs. Results of ongoing RCTs , which should be available in 2018, will provide definitive results on the risk of cardiovascular events and all‐cause mortality associated with SUs vs other antihyperglycaemic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“Recent trials have shown that glucose-lowering treatments may have different, sometimes divergent, effects on cardiovascular risk.(3) Sulphonylureas (SUs) are among the most commonly used Received: 11 May 2016 Revised: 24 October 2016 Accepted: 2 November 2016”
Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes
and the WHO Multinational Study Group, Morrish, N. J., Wang, S.-L., Stevens, L. K., Fuller, J. H., & Keen, H. (2001) · Diabetologia · doi:10.1007/pl00002934 · Cited by 1,288
Dias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013) · Medical Decision Making · doi:10.1177/0272989x12458724 · Cited by 1,207
Vascular disease and diabetes: Is hypoglycaemia an aggravating factor?
Wright, R. J., & Frier, B. M. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.865 · Cited by 336
A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events
Gangji, A. S., Cukierman, T., Gerstein, H. C., Goldsmith, C. H., & Clase, C. M. (2007) · Diabetes Care · doi:10.2337/dc06-1789 · Cited by 308
Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2070 · Cited by 300
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
The ORIGIN Trial Investigators, Mellbin, L. G., Rydén, L., Riddle, M. C., Probstfield, J., Rosenstock, J., Díaz, R., Yusuf, S., & Gerstein, H. C. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht332 · Cited by 247
Marx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., et al. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115570301 · Cited by 212
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationRosenstock, J., Kahn, S. E., Johansen, O. E., Zinman, B., Espeland, M. A., Woerle, H. J., Pfarr, E., Keller, A., Mattheus, M., Baanstra, D., et al. (2019) · JAMA · doi:10.1001/jama.2019.13772 · Cited by 612
Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195
Personalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
Do sulphonylureas still have a place in clinical practice?
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30025-1 · Cited by 116
Self-citation
Metadata
- Authors
- Bain, S., Druyts, E., Balijepalli, C., Baxter, C. A., Currie, C. J., Das, R., Donnelly, R., Khunti, K., Langerman, H., Leigh, P., Siliman, G., Thorlund, K., Toor, K., Vora, J., & Mills, E. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-12-23
- Volume
- 19
- Issue
- 3
- Pages
- 329-335
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2550794647
- Cited by
- 132
- References
- 8
- FWCI
- 13.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A B ayesian meta‐analysis of survival data. https://app.cochat.ai/papers/10.1111/dom.12821
- The paper
- Bain, S., Druyts, E., Balijepalli, C., Baxter, C. A., Currie, C. J., Das, R., Donnelly, R., Khunti, K., Langerman, H., Leigh, P., Siliman, G., Thorlund, K., Toor, K., Vora, J., & Mills, E. J. (2017). Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A B ayesian meta‐analysis of survival data. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12821
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.